# CBGJ398X2204 (NCT02150967)

> A Phase II, Single Arm Study of BGJ398 in Patients With Advanced Cholangiocarcinoma

No report yet. It can be ordered.

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT02150967
- Phase: PHASE2
- Status: TERMINATED
- Sponsor: QED Therapeutics, a BridgeBio company
- Conditions: Advanced Cholangiocarcinoma; FGFR2 Gene Mutation
- Interventions: BGJ398 (infigratinib)
- Enrollment: 143
- Primary outcome: Overall Response Rate (ORR) as Assessed by Blinded Independent Central Imaging Review (BICR)

## Indexed commentary on CBGJ398X2204 so far

Podcasts, YouTube videos and X posts we have indexed that name the trial. This is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.

- X threads: 3

## Order

Focused, $750, price fixed at order: https://www.erudio.com/contact?report=cbgj398x2204-nct02150967